/PCRX
PCRX Stock - Pacira BioSciences, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$26.35+1.82%
+$0.47 (+1.82%) • Dec 19
68
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.76
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).55
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+2.5%upside
Target: $27.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PCRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$26.09 – $26.61
TARGET (TP)$27.00
STOP LOSS$24.24
RISK/REWARD1:0.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.23
52W High$27.64
52W Low$18.17
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $700.97M | $674.98M | $666.82M | $541.53M | $429.65M |
| Gross Profit | $530.54M | $490.31M | $467.53M | $401.28M | $312.32M |
| Gross Margin | 75.7% | 72.6% | 70.1% | 74.1% | 72.7% |
| Operating Income | $-73,371,000 | $87.67M | $60.02M | $89.92M | $46.35M |
| Net Income | $-99,560,000 | $41.95M | $15.91M | $41.98M | $145.52M |
| Net Margin | -14.2% | 6.2% | 2.4% | 7.8% | 33.9% |
| EPS | $-2.15 | $0.91 | $0.35 | $0.95 | $3.41 |
Company Overview
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
55%
Hold / Neutral
4
36%
Sell / Underperform
1
9%
Analyst Consensus🟡 Mixed
6 Bullish5 Neutral/Bearish
Price Targets
$32
Average Target
↑ 20.6% Upside
Now
$8
Low
$32
Average
$66
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Equal Weight | $27 |
| November 17th 2025 | H.C. Wainwright | Initiation | Buy | - |
| July 25th 2025 | Truist | Upgrade | Buy | $30 |
| January 30th 2025 | Truist | Upgrade | Hold | $25← $8 |
| August 13th 2024 | Truist | Downgrade | Sell | $8← $30 |
| August 12th 2024 | Piper Sandler | Downgrade | Neutral | $11← $42 |
| August 12th 2024 | JP Morgan | Downgrade | Underweight | $10← $45 |
| August 12th 2024 | Raymond James | Downgrade | Market Perform | - |
| August 12th 2024 | RBC Capital Mkts | Downgrade | Sector Perform | $14← $37 |
| July 3rd 2024 | Barclays | Downgrade | Equal Weight | $25← $38 |
| March 7th 2024 | JP Morgan | Resumed | Overweight | $45← $80 |
| December 20th 2023 | Raymond James | Initiation | Outperform | $42 |
| August 3rd 2023 | TD Cowen | Upgrade | Outperform | $50 |
| January 31st 2023 | Wedbush | Resumed | Outperform | $60← $88 |
| October 21st 2022 | Jefferies | Resumed | Buy | $66 |
Earnings History & Surprises
PCRXBeat Rate
50%
Last 18 quarters
Avg Surprise
-0.2%
EPS vs Estimate
Beats / Misses
9/7
2 met exactly
Latest EPS
$0.70
Q4 2025
EPS Surprise History
Q1 24
0.0%
$0.89vs$0.89
Q2 24
-3.1%
$0.62vs$0.64
Q3 24
+21.9%
$0.89vs$0.73
Q4 24
+9.7%
$0.79vs$0.72
Q1 25
+16.7%
$0.91vs$0.78
Q2 25
+8.8%
$0.62vs$0.57
Q3 25
+2.8%
$0.74vs$0.72
Q4 25
+7.7%
$0.70vs$0.65
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.84 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.65 | $0.70 | +7.7% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $0.72 | $0.74 | +2.8% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $0.57 | $0.62 | +8.8% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $0.78 | $0.91 | +16.7% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.72 | $0.79 | +9.7% | ✓ BEAT |
Q3 2024 | Jul 30, 2024 | $0.73 | $0.89 | +21.9% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $0.64 | $0.62 | -3.1% | ✗ MISS |
Q1 2024 | Feb 29, 2024 | $0.89 | $0.89 | 0.0% | = MET |
Q4 2023 | Nov 2, 2023 | $0.84 | $0.72 | -14.3% | ✗ MISS |
Q3 2023 | Aug 2, 2023 | $0.81 | $0.78 | -3.7% | ✗ MISS |
Q2 2023 | May 3, 2023 | $0.60 | $0.53 | -11.7% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $0.80 | $0.80 | 0.0% | = MET |
Q4 2022 | Nov 3, 2022 | $0.73 | $0.64 | -12.3% | ✗ MISS |
Q3 2022 | Aug 3, 2022 | $0.85 | $0.51 | -40.0% | ✗ MISS |
Q2 2022 | May 4, 2022 | $0.74 | $0.64 | -13.5% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $0.83 | $0.97 | +16.9% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $0.66 | $0.72 | +9.1% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $0.76 | $0.77 | +1.3% | ✓ BEAT |
Latest News
Barclays Initiates Coverage On Pacira BioSciences with Equal-Weight Rating, Announces Price Target of $27
➖ NeutralBenzinga•Dec 9, 2025, 04:04 PM•Also:
Pacira BioSciences Announces Results From Randomized 30-Patient Pilot Study Evaluating Iovera° Cryoneurolysis Versus Radiofrequency Ablation For Chronic Low Back Pain
➖ NeutralBenzinga•Dec 2, 2025, 01:08 PM
Pacira Biosciences Files Patent Infringement Lawsuit In U.S. District Court Against The WhiteOak Group And Qilu Pharmaceutical Alleging Infringement Of Patents Related To EXPAREL, Pacira's Non-Opioid, Long-Acting Bupivacaine Liposome Injectable Used For Pain Management
📉 NegativeBenzinga•Nov 26, 2025, 09:05 PM
HC Wainwright & Co. Assumes Pacira BioSciences at Buy, Announces Price Target of $38
📈 PositiveBenzinga•Nov 17, 2025, 11:49 AM
Reported Earlier, DOMA Perpetual Urges Pacira BioSciences Board To Hire Bankers And Explore Immediate Sale Of The Business
📉 NegativeBenzinga•Nov 11, 2025, 07:35 AM•Also:
Truist Securities Maintains Buy on Pacira BioSciences, Lowers Price Target to $28
➖ NeutralBenzinga•Nov 7, 2025, 04:52 PM
Pacira BioSciences Lowers FY2025 Sales Guidance from $730.000M-$750.000M to $725.000M-$735.000M vs $737.200M Est
📉 NegativeBenzinga•Nov 6, 2025, 09:13 PM
Pacira BioSciences Q3 Adj. EPS $0.70 Beats $0.65 Estimate, Sales $179.516M Miss $182.552M Estimate
➖ NeutralBenzinga•Nov 6, 2025, 09:03 PM
Pacira BioSciences Completes Patient Enrollment For Part A Of Its Phase 2 Ascend Trial Evaluating PCRX-201, A Locally Administered Gene Therapy For Knee Osteoarthritis
📈 PositiveBenzinga•Nov 5, 2025, 01:06 PM
Pacira Biosciences Inks Exclusive Worldwide License And Collaboration Agreement With AmacaThera For AMT-143, A Non-opioid Analgesic Ropivacaine For Postsurgical Pain Control, AmacaThera Will Receive An Upfront Payment Of $5M With Potential For Milestone Payments And Sales-Based Royalty
📈 PositiveBenzinga•Nov 4, 2025, 12:15 PM
Pacira BioSciences Presents Updated Three-Year Data On PCRX-201 Gene Therapy In Patients With Moderate-to-Severe Osteoarthritis Of The Knee, Showing Clinical Improvements For Up To 156 Weeks Following Single Administration
📈 PositiveBenzinga•Oct 28, 2025, 12:13 PM
Pacira BioSciences Receives Paragraph IV Certification Notice Letter From Qilu Pharmaceutical; Qilu Has Filed Abbreviated New Drug Application For Product Claiming To Be Generic Equivalent Of EXPAREL, Pacira Says Intents To Assert Its IP Rights
📉 NegativeBenzinga•Oct 27, 2025, 12:14 PM
Pacira BioSciences To Present Real-World Evidence Evaluating Clinical Effectiveness And Economic Benefits Of EXPAREL At AMCP Nexus 2025 Annual Meeting
📈 PositiveBenzinga•Oct 23, 2025, 12:02 PM
Pacira BioSciences Receives Paragraph IV Notice Letter For EXPAREL From WhiteOak Group, Subsidiary of Zhejiang Haichang
📉 NegativeBenzinga•Oct 21, 2025, 12:34 PM
Pacira Biosciences To Present New Data From Phase 1 Clinical Trial Evaluating PCRX-201, Gene Therapy Candidate For Osteoarthritis Of Knee, At ACR Convergence 2025 Meeting
📈 PositiveBenzinga•Oct 20, 2025, 08:03 PM
Frequently Asked Questions about PCRX
What is PCRX's current stock price?
Pacira BioSciences, Inc. (PCRX) is currently trading at $26.35 per share. The stock has moved +1.82% today.
What is the analyst price target for PCRX?
The average analyst price target for PCRX is $27.00, based on 1 analyst.
What sector is Pacira BioSciences, Inc. in?
Pacira BioSciences, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is PCRX's market cap?
Pacira BioSciences, Inc. has a market capitalization of $1.20 billion, making it a small-cap company.
Does PCRX pay dividends?
No, Pacira BioSciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANAB
AnaptysBio, Inc.
$49.08
Mkt Cap: $1.4B
BBOT
BridgeBio Oncology Therapeutics Inc.
$12.52
Mkt Cap: $1.0B
CRON
Cronos Group Inc.
$2.96
Mkt Cap: $1.1B
KOD
Kodiak Sciences Inc.
$26.00
Mkt Cap: $1.4B
MNMD
Mind Medicine (MindMed) Inc.
$12.70
Mkt Cap: $1.0B
OCS
Oculis Holding AG
$21.25
Mkt Cap: $1.1B
PHAT
Phathom Pharmaceuticals, Inc.
$17.53
Mkt Cap: $1.2B
TNDM
Tandem Diabetes Care, Inc.
$22.07
Mkt Cap: $1.5B
URGN
UroGen Pharma Ltd.
$22.80
Mkt Cap: $1.1B
XNCR
Xencor, Inc.
$15.55
Mkt Cap: $1.1B
Explore stocks similar to PCRX for comparison